Your browser doesn't support javascript.
loading
Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review.
Jia, Angela Y; Kashani, Rojano; Zaorsky, Nicholas G; Baumann, Brian C; Michalski, Jeff; Zoberi, Jacqueline E; Kiess, Ana P; Spratt, Daniel E.
Afiliação
  • Jia AY; Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland. Electronic address: ajia2@jhmi.edu.
  • Kashani R; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
  • Zaorsky NG; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
  • Baumann BC; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Michalski J; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Zoberi JE; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Kiess AP; Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.
  • Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Pract Radiat Oncol ; 12(4): 294-299, 2022.
Article em En | MEDLINE | ID: mdl-35717043
ABSTRACT
Prostate-specific membrane antigen is a transmembrane protein found predominately on prostate epithelium and is expressed at high levels in prostate cancer. In this review, we discuss the background, clinical data, patient selection, side effects, and necessary resources to deliver lutetium-177 prostate-specific membrane antigen in the research setting, or as standard of care if approved by the United States Food and Drug Administration. Targeted radionuclide therapeutics require understanding of fundamental principles of radiobiology and physics, and radiation oncologists and medical physicists are well-suited to play an integral role in their delivery and treatment response monitoring as key components of a multidisciplinary care team.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2022 Tipo de documento: Article